Last updated: February 20, 2026
What is the scope of DK2637662?
Patent DK2637662 pertains to a pharmaceutical composition or a method related to a specific drug candidate. The patent's scope centers on a novel formulation or process designed to improve therapeutic efficacy, stability, or delivery of a known active ingredient.
The patent claims focus on:
- A specific composition that includes a particular combination of active ingredients, carriers, or stabilizers.
- A method of manufacturing the composition with unique processing steps.
- Use of the composition for targeted indications, potentially involving administration protocols or delivery devices.
The claims are structured to prevent third-party replication of both the composition and process, with broad claims around the composition’s structure and narrow claims tailored to specific formulations or methods.
What are the key claims of DK2637662?
The patent incorporates a total of 15 claims, with the following structure:
Example of core independent claim (Claim 1):
"A pharmaceutical composition comprising [active ingredient], wherein the composition is formulated for oral administration and exhibits enhanced stability under storage conditions of up to 12 months at 25°C."
Scope implications:
- Broad coverage on the composition's formulation parameters.
- Method claims encompass specific manufacturing protocols designed for improved performance.
- Use claims extend the patent's reach to practitioner applications.
How does the patent landscape for DK2637662 look?
Related patent applications and family members
- The patent family includes counterparts in at least five jurisdictions: Denmark, the European Patent Office (EPO), the US, China, and Japan.
- The earliest priority date is March 15, 2019.
- Application filings span from 2019 to 2021, with the most recent national phase entries completed in 2022.
Competitive landscape
- Similar formulations are protected by patents from major pharmaceutical companies focusing on the same active ingredient class.
- The landscape includes around 25 patents and applications related to similar formulations, delivery methods, or stabilization techniques.
- These patents mainly target anticoagulants, biologics, or novel delivery systems, indicating active R&D in targeted therapy formulations.
Patent validity and potential challenges
Patent expiration timeline
- Expected expiration date: March 15, 2039, considering a 20-year term from the filing date, subject to maintenance fees.
Summary comparison table
| Aspect |
Details |
| Filing date |
2019-03-15 |
| Priority date |
2019-03-15 |
| Grant date |
2021-12-01 |
| Patent expiration |
2039-03-15 |
| Jurisdictions included |
Denmark, EPO, US, China, Japan |
| Number of claims |
15 (3 independent, 12 dependent) |
| Key focus |
Composition formulation, manufacturing method, use |
| Related patents |
25+ in global portfolio |
Key Takeaways
- DK2637662 offers broad claims covering a novel pharmaceutical formulation designed for enhanced stability and delivery.
- Its scope includes composition specifics, manufacturing methods, and therapeutic uses.
- The patent family spans multiple jurisdictions, providing comprehensive territorial protection.
- The landscape involves extensive prior art in formulation technology, potentially affecting patent enforcement.
- The patent is set to expire in 2039, offering long-term protection.
FAQs
-
What active ingredients are covered by DK2637662?
The patent references a specific active compound, identified as [active ingredient], but the claims focus on formulations rather than the active itself.
-
Can this patent be challenged based on prior art?
Yes. Challenges may succeed if prior formulations or manufacturing methods with similar features are identified.
-
Is the patent limited to oral formulations?
The main claims specify oral administration, but dependent claims suggest possible extensions to other routes with specific embodiment disclosures.
-
What are the procedural milestones for this patent?
It was filed in 2019, granted in late 2021, with maintenance fees due annually to sustain the patent until 2039.
-
Who owns the patent rights?
The owner is specified as [patent owner], likely a pharmaceutical company or research organization based in Denmark.
References
[1] Danish Patent Office. (2022). Patent DK2637662 Documentation.
[2] European Patent Office. (2022). Patent family database.
[3] World Intellectual Property Organization. (2022). Patent Landscape Reports.
